<div id="readability-page-1"><p>CANADA LIFE ASSURANCE Co lowered its stake in shares of  Boston Scientific Co. (NYSE:BSX - Free Report) by 0.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,778,962 shares of the medical equipment provider's stock after selling 11,410 shares during the period. CANADA LIFE ASSURANCE Co owned about 0.12% of Boston Scientific worth $158,821,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Boston Scientific</strong> alerts:</span></p></div><ul><li>Boston Scientific: Why This MedTech Giant Isn’t Slowing Down</li></ul><p>Several other institutional investors and hedge funds have also modified their holdings of BSX. M&amp;T Bank Corp boosted its position in  Boston Scientific by 0.3% in the 3rd quarter. M&amp;T Bank Corp now owns 106,127 shares of the medical equipment provider's stock worth $8,894,000 after purchasing an additional 370 shares in the last quarter.  Passumpsic Savings Bank acquired a new position in shares of  Boston Scientific in the 3rd quarter valued at $3,015,000.  World Investment Advisors LLC boosted its holdings in  Boston Scientific by 50.9% during the third quarter. World Investment Advisors LLC now owns 11,684 shares of the medical equipment provider's stock worth $979,000 after buying an additional 3,939 shares in the last quarter.  Wilmington Savings Fund Society FSB acquired a new stake in  Boston Scientific during the third quarter valued at $1,175,000.  Finally, Tidal Investments LLC increased its holdings in  Boston Scientific by 8.8% in the third quarter. Tidal Investments LLC now owns 86,507 shares of the medical equipment provider's stock valued at $7,249,000 after buying an additional 6,990 shares in the last quarter. Institutional investors and hedge funds own  89.07% of the company's stock. </p><h2>Boston Scientific Price Performance</h2><p>Shares of BSX stock opened at $95.28 on Thursday. The firm's 50-day moving average is $99.90 and its two-hundred day moving average is $94.18. The company has a market capitalization of $140.93 billion, a PE ratio of 76.22, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a 12 month low of $66.80 and a 12 month high of $107.17. </p><ul><li>Medtronic Stock: Growth On Rise of the Cardiovascular Machines</li></ul><p>Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%.  Analysts predict that  Boston Scientific Co. will post 2.85 earnings per share for the current year. </p><h2>Insider Activity at Boston Scientific</h2><p>In other Boston Scientific news, EVP John Bradley Sorenson sold 1,201 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the sale, the executive vice president now owns 25,443 shares of the company's stock, valued at $2,704,845.33. The trade was a 4.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This represents a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 133,183 shares of company stock worth $13,948,476. Company insiders own  0.50% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>MarketBeat Week in Review – 4/29 - 5/3</li></ul><p>Several research firms have recently issued reports on BSX. Barclays increased their target price on shares of Boston Scientific from $111.00 to $118.00 and gave the stock an &#34;overweight&#34; rating in a research note on Monday, February 10th. Needham &amp; Company LLC upgraded Boston Scientific from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $113.00 price objective for the company in a research report on Wednesday. Wells Fargo &amp; Company upped their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, February 6th. UBS Group boosted their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, February 7th. Finally, Royal Bank of Canada increased their price objective on shares of Boston Scientific from $105.00 to $116.00 and gave the company an &#34;outperform&#34; rating in a report on Thursday, February 6th. One research analyst  has rated the stock with a hold rating, twenty-two have assigned  a buy rating and one  has assigned  a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific  has an average rating of &#34;Buy&#34; and a consensus price target of $110.22.</p><p><b>Check Out Our Latest Stock Report on Boston Scientific</b></p><h2>About Boston Scientific</h2> (Free Report)<p>Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Boston Scientific</li><li>How to Use High Beta Stocks to Maximize Your Investing Profits</li><li>Morgan Stanley: 3 Financial Stocks That Will Thrive in Volatility</li><li>High Flyers: 3 Natural Gas Stocks for March 2022</li><li>Spotify Stock Climbs as Its Growth Strategy Diversifies </li><li>How to trade using analyst ratings</li><li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li></ul><p><strong>Want to see what other hedge funds are holding BSX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Boston Scientific Right Now?</h2><p>Before you consider Boston Scientific, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.</p><p>While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>CANADA LIFE ASSURANCE Co reduced its stake in Boston Scientific Co. (NYSE:BSX) by 0.6% in Q4, owning 1,778,962 shares worth $158.8 million. Other institutional investors also adjusted their holdings. Boston Scientific's stock opened at $95.28, with a market cap of $140.93 billion. The company reported $0.70 EPS, exceeding estimates. Analysts predict $2.85 EPS for the current year. Recent insider sales included EVP John Bradley Sorenson and EVP Arthur C. Butcher, with significant decreases in their ownership. Barclays and Wells Fargo raised their target prices for BSX shares.</p>

Boston Scientific Co. (NYSE:BSX) Shares Sold by CANADA LIFE ASSURANCE Co